Meanwhile, other pharma companies are also developing checkpoint inhibitors for adjuvant RCC, including Roche ... which is testing its Imfinzi (durvalumab) alone and in combination with CTLA4 ...

9, 2024 (HealthDay News) -- For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cisplatin, radiotherapy with adjuvant durvalumab ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

Medscape Medical News, February 08, 2024 GICS 2024 Durvalumab Plus Bevacizumab ... 2024 GUCS 2024 'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer KEYNOTE-564 is the first trial ...

Merck (MSD) has released data from the Phase III KEYNOTE-564 clinical trial of KEYTRUDA, an anti-programmed death receptor-1 (PD-1) therapy, for the adjuvant treatment of renal cell carcinoma (RCC ...

A month later, in August, the FDA approved durvalumab for this indication. Pembrolizumab (Keytruda, Merck) had already been approved 10 months earlier in the neoadjuvant and adjuvant settings in ...